Navigation Links
Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
Date:5/28/2013

PRINCETON, N.J., May 28, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc. (Nasdaq: OMTH), an emerging specialty pharmaceutical company, today announced its financial results for the first quarter of 2013.

Omthera Pharmaceuticals also announced today that it had entered into a definitive merger agreement with AstraZeneca pursuant to which AstraZeneca will acquire Omthera for $12.70 per share, or approximately $323 million. In addition to the cash payment, each Omthera stockholder will receive one Contingent Value Right (CVR) of up to approximately $4.70 for each share they own, equating to $120 million, if specified milestones related to Epanova are achieved, or if a milestone related to global net sales is achieved. This will bring the total potential acquisition value to $443 million.

First Quarter 2013 Financial Results

  • Omthera reported a net loss of $6.3 million for the first quarter of 2013, compared to a net loss of $9.2 million for the first quarter of 2012. Net loss applicable to common stockholders for the first quarter of 2013 was $7.3 million, or $3.08 per common share, compared to a net loss of $10.1 million, or $6.18 per common share, for the first quarter of 2012.
  • Research & Development expenses totaled $0.4 million for the first quarter of 2013, compared to $8.0 million for the first quarter of 2012. The amounts for the first quarter of 2013 and 2012 include approximately $0.1 million and $0.1 million of non-cash stock-based compensation expense, respectively. The decrease in Research & Development expenses is primarily due to the completion in 2012 of the Phase III clinical trials associated with Epanova, compared to current period expenses devoted largely to moving Epanova to regulatory approval.
  • General & Administrative expenses totaled $1.3 million for the first quarter of 2013, compared to $1.1 million for the first quarter of 2012. The amounts for the first quarter of 2013 and 2012 include approximately $0.1 million and $0.1 million of non-cash stock-based compensation expense, respectively. The increase in General & Administrative expenses is largely attributable to legal and consulting costs required for intellectual property filings.
  • As of March 31, 2013, cash and cash equivalents were $14.4 million. This amount does not include the approximate $58 million in net proceeds from the IPO, which closed in April 2013, nor any of the $12.5 million debt facility, which remains undrawn.
  • About Omthera Pharmaceuticals, Inc.Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for dyslipidemia and the treatment of cardiovascular disease. Epanova, currently the Company's sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-3 and omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most abundant forms of omega-3 fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product.

    Forward-Looking Statements:This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the proposed transaction between AstraZeneca and Omthera, Omthera's expectations regarding the filing of its NDA for Epanova, the timing of product approval and commercial launch and management's plans, objectives, and strategies. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, such risks and uncertainties include, but are not limited to, the Company's ability to achieve profitability; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to enter into future collaborations with pharmaceutical companies; the Company's product development activities, including the preparation of its NDA for Epanova, as well as to increase capacity and validate the manufacturing process at our suppliers and build inventory for launch; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidate; the Company's PDUFA date for Epanova; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the accuracy of the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Epanova; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by Epanova; the Company's projected markets and growth in markets; the Company's product formulation and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth discussed under the heading "Risk Factors" contained in Omthera prospectus dated April 11, 2012 filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as any updates to these risk factors filed from time to time in the Company's SEC filings made pursuant to the Securities Exchange Act of 1934, as amended. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

    For more information, please visit www.omthera.com

    Omthera Contact:
    Christian Schade
    Executive Vice President & Chief Financial Officer
    Omthera Pharmaceuticals
    T: 908-741-4399
    E: info@Omthera.com

     Omthera Pharmaceuticals, Inc.Condensed Statement of Operations(In thousands, except per share data)(Unaudited)Three months endedMarch 31,20122013Operating expenses:Research and development$8,049$357General and administrative 1,1311,325Total operating expenses9,1801,682Operating loss(9,180)(1,682)Other income (expense):Interest expense, net—(4,574)Other63Net Loss$(9,174)$(6,253)Dividends on Preferred Stock$(909)$(1,094)Net loss attributable to common shareholders$(10,084)$(7,348)Net loss per share – basic and diluted $(6.18)$(3.08)Weighted average number of shares outstanding (post-split)1,631,7272,383,444 Condensed Balance Sheet Information(In thousands)December 31,March 31,20122013(Unaudited)Cash and cash equivalents $2,505$14,421Total assets3,00818,347Working capital(2,816)(11,991)Convertible notes —17,600Warrant liability, total—4,395Total liabilities 5,48226,860Convertible preferred stock 55,77755,777Stockholders' equity (deficit)$(58,252)$(64,290)(Logo: http://photos.prnewswire.com/prnh/20130528/NY21129LOGO-a)


    '/>"/>
    SOURCE Omthera Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
    2. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    3. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    4. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
    5. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
    6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    7. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    8. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
    9. Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Worth $825 Million by 2017
    10. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
    11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
    (Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
    (Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
    Breaking Medicine Technology:
    (Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
    (Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
    (Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
    (Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
    (Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
    Breaking Medicine News(10 mins):